J.M. Dutton & Associates Announces Investment Opinion: Arbios Systems Strong Speculative Buy Rating in Initiating Coverage by Dutton & Associates.EL DORADO HILLS, Calif. -- J.M. Dutton & Associates initiates coverage of Arbios Systems (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ABOS ABOS American Board of Orthopaedic Surgery ) with a Strong Speculative Buy rating and a $10 price target. The 18-page report by J.M. Dutton senior analyst Bal Bagwat MD, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. is available at www.jmdutton.com, as well as from First Call, Bloomberg, Zacks, Multex, and other leading financial portals. Arbios Systems is a start-up company start-up company A new business. that has designed, tested, and desires to commercialize medical devices for the treatment of acute liver failure Acute liver failure is the appearance of severe complications rapidly after the first signs of liver disease (such as jaundice), and indicates that the liver has sustained severe damage (loss of function of 80-90% of liver cells). , as well as other potential future indications, such as the treatment of sepsis. The Company's product pipeline consists of SEPET SEPET System Electrical Performance and Evaluation Test (TM), a patent-pending selective plasma filtration therapy cartridge, and bioartificial liver devices (BAL), such as HepatAssist-2(TM), and next-generation product, Liveraid(TM). The current potential U.S. commercial market for liver support devices, such as SEPET(TM), HepatAssist-2(TM), and Liveraid(TM), has been estimated to be approximately $900 million per year ($1.4 billion worldwide), and rising due to demographics. If clinical trials confirm pre-clinical experimental results that SEPET(TM) hemofiltration significantly lowers the levels of hepatic blood toxins, improves intra-cranial pressure levels, and improves hepatic encephalopathy hepatic encephalopathy n. See portal-systemic encephalopathy. Hepatic encephalopathy Also called liver encephalopathy or hepatic coma, this is a disorder in which brain function deteriorates because toxic substances, , acute liver failure patients could be transferred from the ICU ICU intensive care unit. ICU abbr. intensive care unit ICU see intensive care unit. ICU to a transitional care unit or ward earlier. Financial implications for shorter ICU stays are significant -- estimated $2.12 billion net US healthcare savings. We review the risks and opportunities of ABOS, and note the highly qualified and experienced management team. About Dutton & Associates Dutton & Associates is one of the largest independent investment research firms in the U.S. Its 29 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 85 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors. The cost of enrollment in our one-year continuing research program is US $33,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton & Associates received $33,000 from the Company for 4 Research Reports with coverage commencing on 1/24/2005. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion